Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations [0.03%]
基因治疗载体给药后脱落的rAAV颗粒细胞结合能力评估：对环境风险和卫生建议的意义
Tobias Fleischmann
Tobias Fleischmann
Background: Currently, adeno-associated viruses (AAVs) are the most commonly used in vivo gene therapy (GT) vector platform. Risks posed to the environment, including the public, have not been well studied in the past. Th...
Correction [0.03%]
改正通知书
Dynamics of biological markets with multiple biosimilar competitors in the United States [0.03%]
美国多种生物类似药竞争下的生物制药市场动力学分析
Morgane C Mouslim,Mariana P Socal,Antonio J Trujillo
Morgane C Mouslim
Background: The dynamics of biological markets with multiple biosimilar competitors in the United States are poorly understood. Moreover, due to confidentiality issues, the relationship between originator biologic net pri...
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review [0.03%]
抗CD20单克隆抗体治疗复发慢性淋巴细胞白血病的疗效和安全性：综述
Magdalena Witkowska,Agata Majchrzak,Paweł Robak et al.
Magdalena Witkowska et al.
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the introduction of antibody-based therapie...
Christopher White,Peter M Irving
Christopher White
Introduction: Treatment of ulcerative colitis (UC) aims to reduce symptoms and complications by decreasing intestinal inflammation. A proportion of patients do not respond to, do not tolerate, or are inappropriate candida...
Developing combination therapies with biologics in triple-negative breast cancer [0.03%]
三阴性乳腺癌的生物制剂联合疗法研究进展
Gilda Gaudio,Enzo Martino,Gloria Pellizzari et al.
Gilda Gaudio et al.
Introduction: Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). The optimization o...
Probiotic therapy as a promising strategy for gestational diabetes mellitus management [0.03%]
益生菌疗法作为妊娠期糖尿病管理的潜在策略
Deborah Emanuelle de Albuquerque Lemos,José Luiz de Brito Alves,Evandro Leite de Souza
Deborah Emanuelle de Albuquerque Lemos
Introduction: Gestational diabetes mellitus (GDM) has become the most common pregnancy medical complication, and its prevalence has increased in recent years. The GDM treatment primarily relies on adopting healthy eating ...
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art [0.03%]
生物制剂靶向及联合免疫治疗胃癌的现状
Jane E Rogers,Qiong Gan,Rebecca E Waters et al.
Jane E Rogers et al.
Introduction: Gastric adenocarcinoma (GAC) remains a prevalent cancer worldwide and its incidence is increasing in South America. The heterogenous nature of GAC makes advances in management challenging. ...
The frontier of neoadjuvant therapy in non-small cell lung cancer beyond PD-(L)1 agents [0.03%]
PD-(L)1药物之外探索非小细胞肺癌新辅助治疗的前沿方向
Marco Sposito,Serena Eccher,Ilaria Scaglione et al.
Marco Sposito et al.
Introduction: While surgical resection is the cornerstone of treatment for resectable lung cancer, neoadjuvant/adjuvant chemotherapy has shown limited improvement in survival rates over the past decades. With the success ...
Unmet needs in cervical cancer - can biological therapies plug the gap? [0.03%]
宫颈癌的未满足需求——生物疗法能否填补空白？
Michelle Greenman,Yifan Emily Chang,Blair McNamara et al.
Michelle Greenman et al.
Introduction: Cervical cancer remains one of the most common gynecologic malignancies worldwide. A disproportionate burden of cases occurs in developing countries due to inadequate screening and treatment. Even among pati...